Dr. Shaji K. Kumar, M.D.
Claim this profileMayo Clinic in Rochester
Expert in Multiple Myeloma
Expert in Plasma Cell Neoplasms
19 reported clinical trials
27 drugs studied
Area of expertise
1Multiple Myeloma
Global LeaderMMRF002
early stage
Stage I
2Plasma Cell Neoplasms
Global LeaderMMRF002
early stage
Stage I
Affiliated Hospitals
Clinical Trials Shaji K. Kumar, M.D. is currently running
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
Combination Chemotherapy
for Multiple Myeloma
This phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma. Chemotherapy drugs, such as carfilzomib, daratumumab, lenalidomide, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help determine if patients who have a small amount of cancer left after the initial treatment, called minimal residual disease, will benefit from the drug combination.
Recruiting1 award Phase 218 criteria
More about Shaji K. Kumar, M.D.
Clinical Trial Related12 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Shaji K. Kumar, M.D. has experience with
- Lenalidomide
- Daratumumab
- Dexamethasone
- Belantamab Mafodotin
- Carfilzomib
- Venetoclax
Breakdown of trials Shaji K. Kumar, M.D. has run
Multiple Myeloma
Plasma Cell Neoplasms
Amyloidosis
AL Amyloidosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Shaji K. Kumar, M.D. specialize in?
Shaji K. Kumar, M.D. focuses on Multiple Myeloma and Plasma Cell Neoplasms. In particular, much of their work with Multiple Myeloma has involved MMRF002 patients, or patients who are early stage.
Is Shaji K. Kumar, M.D. currently recruiting for clinical trials?
Yes, Shaji K. Kumar, M.D. is currently recruiting for 6 clinical trials in Rochester Minnesota. If you're interested in participating, you should apply.
Are there any treatments that Shaji K. Kumar, M.D. has studied deeply?
Yes, Shaji K. Kumar, M.D. has studied treatments such as Lenalidomide, Daratumumab, Dexamethasone.
What is the best way to schedule an appointment with Shaji K. Kumar, M.D.?
Apply for one of the trials that Shaji K. Kumar, M.D. is conducting.
What is the office address of Shaji K. Kumar, M.D.?
The office of Shaji K. Kumar, M.D. is located at: Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States. This is the address for their practice at the Mayo Clinic in Rochester.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.